AstraZeneca PLC’s checkpoint inhibitor, Imfinzi (durvalumab), combined with standard chemotherapy, has been associated with a statistically significant 27% reduction in death (with a hazard ratio of 0.73) versus chemotherapy alone when given as first-line therapy for patients with extensive-stage small cell lung cancer in the CASPIAN study.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?